Radiation boost for immunotherapy in lung cancer trial
NCT ID NCT03436056
Summary
This early-stage study tested whether adding a short, high-dose course of targeted radiation (SBRT) to a standard immunotherapy drug (pembrolizumab) was safe for people with advanced non-small cell lung cancer. The goal was to see if the radiation could help the immunotherapy work better to control the cancer. The study was terminated early after enrolling only 2 of a planned 24 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Royal Marsden NHS Foundation Trust
Sutton, Surrey, SM2 5PT, United Kingdom
Conditions
Explore the condition pages connected to this study.